Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Non-Current Assets (2016 - 2025)

Myriad Genetics (MYGN) has disclosed Non-Current Assets for 16 consecutive years, with $374.0 million as the latest value for Q4 2025.

  • Quarterly Non-Current Assets fell 48.74% to $374.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.9 billion through Dec 2025, down 40.31% year-over-year, with the annual reading at $374.0 million for FY2025, 48.74% down from the prior year.
  • Non-Current Assets for Q4 2025 was $374.0 million at Myriad Genetics, down from $383.3 million in the prior quarter.
  • The five-year high for Non-Current Assets was $1.0 billion in Q1 2021, with the low at $374.0 million in Q4 2025.
  • Average Non-Current Assets over 5 years is $773.7 million, with a median of $830.4 million recorded in 2022.
  • The sharpest move saw Non-Current Assets grew 10.55% in 2022, then plummeted 51.36% in 2025.
  • Over 5 years, Non-Current Assets stood at $835.9 million in 2021, then increased by 10.55% to $924.1 million in 2022, then fell by 9.87% to $832.9 million in 2023, then decreased by 12.4% to $729.6 million in 2024, then plummeted by 48.74% to $374.0 million in 2025.
  • According to Business Quant data, Non-Current Assets over the past three periods came in at $374.0 million, $383.3 million, and $393.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.